# OnCo record oesophageal-adenocarcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/oesophageal-adenocarcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "oesophageal-adenocarcinoma" ;
  schema:name "Oesophageal and junctional adenocarcinoma"@en ;
  schema:alternateName "Esophageal adenocarcinoma"@en, "EAC"@en, "Gastro-oesophageal junction adenocarcinoma"@en, "Barrett's cancer"@en ;
  schema:description "Adenocarcinoma of the lower oesophagus and junction grows out of Barrett's oesophagus, the change in the lining caused by long-standing acid reflux. Chemotherapy or chemoradiation before surgery is standard, and HER2, PD-L1 and claudin 18.2 now guide drugs for advanced disease as they do in stomach cancer."@en ;
  schema:url <https://onco.cc/cancers/oesophageal-adenocarcinoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Esophageal_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Esophageal_cancer> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/> ;
  onco:trials <https://onco.cc/trials/esopec/>, <https://onco.cc/trials/flot4/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-checkmate-649-lancet-2021/>, <https://onco.cc/key-papers/paper-flot4-lancet-2019/>, <https://onco.cc/key-papers/paper-cross-nejm-2012/>, <https://onco.cc/key-papers/paper-keynote-590-lancet-2021/> ;
  onco:pipeline <https://onco.cc/drugs/zolbetuximab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:standardOfCare <https://onco.cc/technologies/endoscopic-resection/>, <https://onco.cc/drugs/flot/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/trials/cross/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/zolbetuximab/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/cldn18-2/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/paclitaxel/> .